News

InspireMD, CGuard, PARADIGM study, EuroPCR 2015, Musialek

InspireMD Inc. announced that its CGuard embolic prevention system reported positive results in the PARADIGM study at the EuroPCR conference, May 22 in Paris. The study was lead by principle...

Stentys, Xposition S, CE Mark, EuroPCR

Stentys announced in April that it received CE Marking for its new Self-Apposing stent system ahead of plan. The designation will allow the company to market the new products in Europe and in...

Karam Moon, M.D., winner of the DePuy Synthes Cerebrovascular Section Resident/Fellow Award, presented his research, The Myth of Restenosis after Carotid Angioplasy and Stenting, at the American...

Xposition S, Stentys, SETUP trial, results, EuroPCR, EuroIntervention

Stentys announced that the findings of the first Xposition clinical experience, as part of the SETUP trial, were presented at the EuroPCR conference in May. The results of this study were also...

Patients who received a bare metal coronary stent did not display significant differences in rates of adverse events with an additional 18 months of dual antiplatelet therapy rather than placebo,...

Biotronik, Pulsar-18, Michael Lichtenberg, study

Biotronik announced the publication of promising clinical results regarding its Pulsar-18 stent platform. Adding to the similarly encouraging data collected in the earlier 4EVER and PEACE...

Fantom, REVA Medical, FANTOM II trial, ACC

REVA Medical Inc. announced the initiation of patient enrollment in the FANTOM II clinical trial of its Fantom sirolimus-eluting bioresorbable scaffold in March. The scaffold, made from REVA's...

enroute carotid stent

Silk Road Medical Inc. announced the company received U.S. Food & Drug Administration (FDA) 510(k) clearance for its Enroute transcarotid neuroprotection system (NPS). The Enroute transcarotid...

electronic stents, bioresorbable electronic stent, BES

With the recent innovation of flexible microelectronic sensor circuits that can be made from bioresorbable materials, it is now possible to create “electronic stents” to monitor a treated lesion...

OrbusNeich, Combo, EPC, HARMONEE study, U.S.

OrbusNeich has announced that the first U.S. patient has been enrolled in the HARMONEE (Harmonized Assessment by Randomized, Multi-center Study of OrbusNEich's COMBO StEnt) stent study. The study...

ART, PBS, pure bioresorbable scaffold, CE Mark

Privately-held company Arterial Remodeling Technologies (ART) announced CE Mark clearance for its next-generation drug-free, pure bioresorbable scaffold used to treat coronary artery disease. The...

Boston Scientific, Synergy, EVOLVE I, EVOLVE II, EuroPCR 2015, results

Boston Scientific reported positive, long-term data from the EVOLVE Trial of the Synergy everolimus-eluting bioabsorbable polymer platinum chromium coronary stent system, with no new major adverse...

Amaranth Medical, Fortitude BRS, MEND-II, RENASCENT, EuroPCR 2015

Amaranth Medical announced plans to report clinical results from the company's ongoing trial of its second-generation Fortitude sirolimus-eluting bioresorbable scaffold (BRS) at EuroPCR 2015. Juan...

Abbott, Absorb, dissolving stent, resorbable, CE Mark, Europe

Abbott announced that it has received CE Mark for the latest advancement of its Absorb stent system, called Absorb GT1. Absorb GT1 combines a fully dissolving stent with a next-generation delivery...

Boston Scientific, investors, cardiology, growth, expansion

Boston Scientific Corp. presented an overview of its continued business momentum and long-term growth strategies at a meeting with the investment community May 1.

Boston Scientific, Eluvia, MAJESTIC trial, vascular stent, PAD

A key trial evaluating the Boston Scientific Eluvia drug-eluting vascular stent system met its primary endpoint, with more than 94 percent of the lesions treated for peripheral arterial disease (...

carotid artery stenting, F-EPD, P-EPD, ACC, embolic protection devices

A study published in JACC: Cardiovascular Interventions showed that in-hospital and 30-day stroke or death rates were equally low with either a distal filter embolic protection device (F-...

BEST Trial

Despite the advent of a new generation of stents, patients with multiple narrowed arteries in the heart who received coronary artery bypass grafting fared better than those whose arteries were...

Medtronic, Drug Filled Stent, clinical trial, ACC

Medtronic plc unveiled the preclinical outcomes of its novel Drug-Filled Stent (DFS) at the 64th Annual Scientific Session of the American College of Cardiology (ACC). The preclinical data showed...